Alex Toker is a Professor in the Department of Pathology at Harvard Medical School. His research focuses on the molecular biology of cancer, particularly the phosphoinositide 3-kinase (PI3K) and AKT signaling pathways. Over the years, he has made significant contributions to understanding how AKT proteins and their isoforms regulate cancer cell motility and invasion, identifying critical substrates involved in these processes. Toker's laboratory has been pivotal in uncovering the oncogenic mechanisms of AKT and has investigated small molecule inhibitors of AKT that are currently in clinical trials. His findings shed light on metabolic vulnerabilities in cancer cells, proposing novel strategies for targeted therapies. Additionally, he has a strong commitment to mentorship and graduate education, actively training students and junior scientists within the Biological Biomedical Sciences PhD program. His work has broad implications for cancer therapy, aiming to overcome resistance mechanisms and improve treatment outcomes.